Helps diagnose congenital and acquired abnormalities, renal failure, urinary tractโฆ. Sold as Technescan MAG3, Technetium TC 99M Mertiatide. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 22, 2026, FDA lists 4 applications for Technetium TC-99M mertiatide kit (sold as Technescan MAG3, Technetium TC 99M Mertiatide), first approved Jun 15, 1990, with 1 new use approved and 0 published complete response letters.
| Jun 15, 1990 | Technescan MAG3NDA 19882 ยท New molecular entity | Curium | 8 | Marketed |
| Jul 12, 2019 | Technetium TC99M MertiatideANDA 208994 | Sun Pharmaceutical Industries | 0 | Marketed |
| Feb 6, 2020 | Technetium TC99M MertiatideANDA 206489 | Medi-Radiopharma | 0 | Marketed |
| Jan 30, 2023 | Technetium TC 99M MertiatideNDA 216820 ยท New formulation or manufacturer | Jubilant Draximage | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA